| Todd Erickson, OD | |
|
340 W Center St, Suite B, Kalispell, MT 59901-4032 | |
| (406) 755-5171 | |
| (406) 755-5182 |
| Full Name | Todd Erickson |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 31 Years |
| Location | 340 W Center St, Kalispell, Montana |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013071455 | NPI | - | NPPES |
| 048-3769 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 593 (Montana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Vision Clinic Pllc | 2769474436 | 6 |
News Archive
Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive disorder (MDD) based on multiple standard measures of outcome for depression. EB-1010 also improved measures of anhedonia, a hallmark symptom of MDD, which is characterized by the inability to experience pleasure.
In the battle between humans and infectious bacteria, humans have had the advantage, at least since antibiotics were introduced into our arsenal 70 or so years ago. Now, however, our weapons appear to be turning against us as germs have found ways to outfox antibiotics…. A second challenge is to keep a steady stream of new antibiotics in the pipeline, and this is where the big pharmaceutical companies based in Europe and the U.S. come in….
Although much work remains to be done, a United Nations global reporting system on HIV/AIDS has already yielded an "unequaled wealth of data" on progress toward meeting UN targets for responding to the global HIV epidemic. An update on the development of the UN General Assembly Special Session on HIV/AIDS (UNGASS) global reporting system appears in a special supplement to JAIDS: Journal of Acquired Immune Deficiency Syndromes.
In a small clinical trial led by the Johns Hopkins Bloomberg School of Public Health, researchers say that a promising single-dose dengue vaccine, developed by scientists at the National Institutes of Health, was 100 percent effective in preventing human volunteers from contracting the virus, the most prevalent mosquito-borne virus in the world.
› Verified 7 days ago
| Provider Name | Vision Clinic Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1528240454 PECOS PAC ID: 2769474436 Enrollment ID: O20040401000976 |
News Archive
Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive disorder (MDD) based on multiple standard measures of outcome for depression. EB-1010 also improved measures of anhedonia, a hallmark symptom of MDD, which is characterized by the inability to experience pleasure.
In the battle between humans and infectious bacteria, humans have had the advantage, at least since antibiotics were introduced into our arsenal 70 or so years ago. Now, however, our weapons appear to be turning against us as germs have found ways to outfox antibiotics…. A second challenge is to keep a steady stream of new antibiotics in the pipeline, and this is where the big pharmaceutical companies based in Europe and the U.S. come in….
Although much work remains to be done, a United Nations global reporting system on HIV/AIDS has already yielded an "unequaled wealth of data" on progress toward meeting UN targets for responding to the global HIV epidemic. An update on the development of the UN General Assembly Special Session on HIV/AIDS (UNGASS) global reporting system appears in a special supplement to JAIDS: Journal of Acquired Immune Deficiency Syndromes.
In a small clinical trial led by the Johns Hopkins Bloomberg School of Public Health, researchers say that a promising single-dose dengue vaccine, developed by scientists at the National Institutes of Health, was 100 percent effective in preventing human volunteers from contracting the virus, the most prevalent mosquito-borne virus in the world.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Todd Erickson, OD 340 W Center St, Suite B, Kalispell, MT 59901-4032 Ph: (406) 755-5171 | Todd Erickson, OD 340 W Center St, Suite B, Kalispell, MT 59901-4032 Ph: (406) 755-5171 |
News Archive
Euthymics Bioscience, Inc. today will present Phase II clinical data demonstrating that its lead product candidate EB-1010, a next-generation antidepressant, is effective for treating major depressive disorder (MDD) based on multiple standard measures of outcome for depression. EB-1010 also improved measures of anhedonia, a hallmark symptom of MDD, which is characterized by the inability to experience pleasure.
In the battle between humans and infectious bacteria, humans have had the advantage, at least since antibiotics were introduced into our arsenal 70 or so years ago. Now, however, our weapons appear to be turning against us as germs have found ways to outfox antibiotics…. A second challenge is to keep a steady stream of new antibiotics in the pipeline, and this is where the big pharmaceutical companies based in Europe and the U.S. come in….
Although much work remains to be done, a United Nations global reporting system on HIV/AIDS has already yielded an "unequaled wealth of data" on progress toward meeting UN targets for responding to the global HIV epidemic. An update on the development of the UN General Assembly Special Session on HIV/AIDS (UNGASS) global reporting system appears in a special supplement to JAIDS: Journal of Acquired Immune Deficiency Syndromes.
In a small clinical trial led by the Johns Hopkins Bloomberg School of Public Health, researchers say that a promising single-dose dengue vaccine, developed by scientists at the National Institutes of Health, was 100 percent effective in preventing human volunteers from contracting the virus, the most prevalent mosquito-borne virus in the world.
› Verified 7 days ago
Stanley R Smith, OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 580 N Meridian Rd, Kalispell, MT 59901 Phone: 406-755-5910 Fax: 406-756-5701 | |
Dr. Marie Roach, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 175 Timberwolf Pkwy, Kalispell, MT 59901 Phone: 406-257-2020 Fax: 406-257-5554 | |
Dr. Jonathan Franklin Olsen, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 175 Timberwolf Pkwy, Kalispell, MT 59901 Phone: 406-257-2020 Fax: 406-257-5554 | |
Dr. Douglas Craig Dolan, OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 20 Village Loop Rd, Kalispell, MT 59901 Phone: 406-756-8420 Fax: 406-756-0119 | |
Nicholas S Chamberlain, OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 580 N Meridian Rd, Kalispell, MT 59901 Phone: 406-755-5910 Fax: 406-756-5701 | |
Kyle Matthew Smalley, O.D. Optometrist Medicare: May Accept Medicare Assignments Practice Location: 580 N Meridian Rd, Kalispell, MT 59901 Phone: 406-755-5910 Fax: 406-756-5701 |